ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Total liabilities 2016–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) total liabilities at each fiscal year-end, per SEC filings.
$234.1MFY2024 · since FY2016: $68.4M → $234.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $234.1M | -3.7% |
| FY2023 | $243.1M | -1.6% |
| FY2022 | $247.0M | -6.3% |
| FY2021 | $263.6M | +139.8% |
| FY2020 | $109.9M | +89.8% |
| FY2019 | $57.9M | +94.0% |
| FY2018 | $29.9M | -61.8% |
| FY2017 | $78.2M | +14.3% |
| FY2016 | $68.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ADAPY financial trends
ADAPY RevenueADAPY Net incomeADAPY Net marginADAPY Gross profitADAPY Gross marginADAPY Operating incomeADAPY Operating marginADAPY Operating cash flowADAPY Free cash flowADAPY Capital expendituresADAPY Return on equityADAPY Stock buybacksADAPY Dividends paidADAPY Total assetsADAPY Shareholders’ equityADAPY overview →